Synthesis, biological activity and molecular modelling studies of tricyclic alkylimidazo-, pyrimido- and diazepinopurinediones
Open Access
- 2 April 2013
- journal article
- research article
- Published by Springer Nature in Purinergic Signalling
- Vol. 9 (3) , 395-414
Abstract
Syntheses and biological activities of imidazo-, pyrimido- and diazepino[2,1-f]purinediones containing N-alkyl substituents (with straight, branched or unsaturated chains) are described. Tricyclic derivatives were synthesized by the cyclization of 8-bromo-substituted 7-(2-bromoethyl)-, 7-(3-chloropropyl)- or 7-(4-bromobutyl)-theophylline with primary amines under various conditions. Compound 22 with an ethenyl substituent was synthesized by dehydrohalogenation of 9-(2-bromoethyl)-1,3-dimethyltetrahydropyrimido[2,1-f]purinedione. The obtained derivatives (5–35) were initially evaluated for their affinity at rat A1 and A2A adenosine receptors (AR), showing moderate affinity for both adenosine receptor subtypes. The best ligands were diazepinopurinedione 28 (K i = 0.28 μM) with fivefold A2A selectivity and the non-selective A1/A2A AR ligand pyrimidopurinedione 35 (K i A1 = 0.28 μM and K i A2A = 0.30 μM). The compounds were also evaluated for their affinity at human A1, A2A, A2B and A3 ARs. All of the obtained compounds were docked to the A2A AR X-ray structure in complex with the xanthine-based, potent adenosine receptor antagonist—XAC. The likely interactions of imidazo-, pyrimido- and diazepino[2,1-f]purinediones with the residues forming the A2A binding pocket were discussed. Furthermore, the new compounds were tested in vivo as anticonvulsants in maximal electroshock, subcutaneous pentylenetetrazole (ScMet) and TOX tests in mice (i.p.). Pyrimidopurinediones showed anticonvulsant activity mainly in the ScMet test. The best derivative was compound 11, showing 100 % protection at a dose of 100 mg/kg without symptoms of neurotoxicity. Compounds 6, 7, 8 and 14 with short substituents showed neurotoxicity and caused death. In rat tests (p.o.), 9 was characterized by a high protection index (>13.3). AR affinity did not apparently correlate with the antiepileptic potency of the compounds.Keywords
This publication has 51 references indexed in Scilit:
- G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactionsPurinergic Signalling, 2012
- Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and CaffeineStructure, 2011
- Recent developments in adenosine receptor ligands and their potential as novel drugsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An UpdatePharmacological Reviews, 2011
- Evaluation of Homology Modeling of G-Protein-Coupled Receptors in Light of the A2AAdenosine Receptor Crystallographic StructureJournal of Medicinal Chemistry, 2009
- The 2.6 Angstrom Crystal Structure of a Human A2AAdenosine Receptor Bound to an AntagonistScience, 2008
- Molecular modeling of A1and A2Aadenosine receptors: Comparison of rhodopsin‐ and β2‐adrenergic‐based homology models through the docking studiesJournal of Computational Chemistry, 2008
- Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in ratsBehavioural Brain Research, 2007
- Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studiesPurinergic Signalling, 2006
- The Relationship between Spectral Shifts and Structural Changes in Uric Acids and Related CompoundsJournal of the American Chemical Society, 1955